Phase 2 N=39 Lower Dose Chemotherapy Given More Frequent With Avastin to Treat Advanced Non-Squamous Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer
Primary: Progression-Free Survival (PFS) — 8.5 months
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=28 Phase II Study of Cabazitaxel-XRP6258 in Advanced Non-Small Cell Lung Cancer
Non-small Cell Lung Cancer (NSCLC) · Stage IV NSCLC · Metastatic NSCLC
Primary: Objective Response Rate — 0; 1 participants
Phase 2 N=55 A Study of Advanced or Metastatic Non-small Cell Lung Cancer
Non Small Cell Lung Cancer
Primary: Overall Tumor Response - Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR) [Overall Response Rate (ORR)] — 9.1 percentage of…
Phase 2 N=32 Anti-angiogenesis Agent AG-013736 in Patients With Advanced Non-Small Cell Lung Cancer
Lung Neoplasms · Carcinoma, Non-small Cell Lung
Primary: Percentage of Participants With Objective Response (OR) — 9.4 Percentage of participants
Phase 2 N=53 The 'MADe IT' Clinical Trial: Molecular Analyses Directed Individualized Therapy for Advanced Non-Small Cell Lung Cancer
Carcinoma, Non-Small-Cell Lung
Primary: Best Disease Response After a Maximum of Six Cycles. — 0; 23; 23; 6 Participants
Phase 2 N=26 Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-small Cell Lung Cancer
Recurrent Non-Small Cell Lung Carcinoma · Stage IV Non-Small Cell Lung Cancer
Primary: Overall Response Rate (Complete and Partial Response) Defined by RECIST 1.1 Criteria — 0; 9; 6; 6 Participants
Phase 2 N=133 Chemotherapy With Pemetrexed in Combination With Platinum for Advanced Non-Small Cell Lung Cancer (NSCLC)
Non-Small-Cell Lung Cancer
Primary: Percentage of Participants Surviving Progression-Free at 6 Months (Progression Free Survival [PFS] Rate) — 52.8; 39.3 percentage
Phase 2 N=137 A Study of MetMAb Administered to Patients With Advanced Non-Small Cell Lung Cancer, in Combination With Tarceva (Erlotinib)
Non-Small Cell Lung Cancer
Primary: Progression-free Survival — 2.2; 2.6 months — p=0.6873
Phase 2 N=226 Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
Non-Small Cell Lung Cancer
Primary: Overall Survival (OS) — 10.9; 10.7 months — p=0.5157
Phase 2 N=35 AB-16B5 Combined With Docetaxel in Subjects With Metastatic Non-Small Cell Lung Cancer (EGIA-002)
NSCLC Stage IV
Primary: Objective Response Rate (ORR) — 6 Participants
N/A N=29 Stereotactic Body Radiation Therapy (SBRT) in Metastatic Non-small Cell Lung Cancer
Non-Small-Cell Lung Carcinoma · Liver Cancer · Adrenal Cancer
Primary: Progression-free Survival — 11.2 months
Phase 3 N=419 AZD9291 (Osimertinib) Versus Platinum-Based Doublet-Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Anticancer Treatment
Primary: Progression Free Survival (PFS) by Investigator Assessment — 10.1; 4.4 Months — p=<0.001
Phase 2 N=103 ONO-4538 Study in Patients With Advanced Non-Small Cell Lung Cancer
Advanced Non-small Cell Lung Cancer (NSCLC)
Primary: Response Rate (Centrally Assessed) — 13.6; 19.6 percentage of participants
Phase 2 N=37 BAY 43-9006 (Sorafenib) to Treat Relapsed Non-Small Cell Lung Cancer
Non-Small-Cell Lung Carcinoma
Primary: Response Rate — 6 percentage of participants
Phase 3 N=260 Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer
Primary: Survival Without Grade 3 or 4 Toxicity — 3.2; 0.7 months — p=<0.001
Phase 2 N=811 An Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) Monotherapy in Subjects With Advanced or Metastatic Squamous Cell (Sq) Non-Small Cell Lung Cancer (NSCLC) Who Have Received at Least One Prior Systemic Regimen for the Treatment of Stage IIIb/IV SqNSCLC
Non-Small Cell Lung Cancer
Primary: Number of Participants With High Grade (Grade 3, 4 and 5) Treatment Related Select Adverse Events — 1; 7; 0; 1 Participants
Phase 2 N=11 LCI-LUN-ABR-001: Carbo With Nab-Paclitaxel in Patients With Advanced NSCL Cancer
Lung Cancer
Primary: Number of Participants With a Response — 4 Participants — p=0.161
Phase 3 N=720 PF-00299804 in Stage IIIB or Stage IV Non-Small Cell Lung Cancer Not Responding to Standard Therapy for Advanced or Metastatic Cancer
Lung Cancer
Primary: Overall Survival — 6.83; 6.31 Months — p=0.506
Phase 2 N=288 Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin for Advanced NSCLC Metastatic Non-small Cell Lung Cancer
Non-small Cell Lung Cancer · Efficacy
Primary: Progression Free Survival (PFS) — 168; 140 day
Phase 2 N=137 A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]
Non-Small Cell Lung Cancer
Primary: Percentage of Participants With Objective Response According to Modified Response Evaluation Criteria in Solid Tumors (RECIST) — 32; 21; 23 percentage of participants
Phase 2 N=53 Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib
Non-Small Cell Lung Cancer
Primary: Progression-free Survival (PFS) — 3.1; 1.9 months
Phase 4 N=2,252 A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
Non-Squamous Non-Small Cell Lung Cancer
Primary: Number of Participants With Adverse Events of Special Interest — 687; 672; 26; 30 participants
Phase 2 N=166 Sorafenib/Erlotinib Versus Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)
Non-Small Cell Lung Cancer
Primary: Overall Objective Response Rate (ORR) — 8.1; 10.9 percentage of participants
Phase 3 N=453 A Study of Atezolizumab Compared With a Single-Agent Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Doublet Chemotherapy
Non-Small Cell Lung Cancer
Primary: Overall Survival (OS) — 10.3; 9.2 Months — p=0.025
Phase 2 N=69 Gemcitabine, Docetaxel, and Cetuximab in Patients With Unresectable Advanced Non-Small Cell Lung Cancer
Lung Cancer
Primary: Overall Clinical Response Rate — 17 Percentage of participants
Phase 2 N=53 ALT-803 Plus Nivolumab in Patients With Pretreated, Advanced or Metastatic Non-Small Cell Lung Cancer
Non-small Cell Lung Cancer
Primary: Presence or Absence of a Dose Limiting Toxicity (DLT) of ALT-803 in Combination With Nivolumab — 3; 3; 6; 8 Participants
Phase 2 N=72 Pemetrexed and Gemcitabine in Patients With Advanced Non-Small Cell Lung Cancer
Lung Cancer
Primary: Overall Response Rate — 26 Percentage of participants
Phase 2 N=153 A Study of AUY922 in Non-small-cell Lung Cancer Patients Who Have Received Previous Two Lines of Chemotherapy.
Non-small-cell Lung Cancer
Primary: Response Assessment by Study Stratum - Per Investigator Assessment — 0; 6; 3; 7 Participants
Phase 2 N=137 A Study of Paclitaxel/Carboplatin With or Without Olaratumab (IMC-3G3) in Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Non-Small Cell Lung Cancer
Primary: Progression-Free Survival (PFS) — 19.1; 19.0; 8.3 weeks — p=0.2133
Phase 2 N=110 First-Line Treatment of A Comparison of 2 Treatments in Elderly Patients With Advanced NSCLC
Lung Cancer
Primary: Time to Progression (TTP), the Length of Time, in Months, That Patients Were Alive From Their First Date of Protocol Treatment Until Worsening of Their Disease — 4.7…